AzTrials
AzTrials

Multi-antibiotic ResistanceNCT04181112

Fecal Transplant for MDRO Decolonization

A study testing Fecal Microbiota Transplantation (FMT) in people with Multi-antibiotic Resistance, run by University of British Columbia at 2 sites in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This is a trial designed to determine whether fecal microbiota transplantation (FMT) can eliminate highly drug-resistant bacteria from the intestinal tract of renal transplant patients. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Multi-antibiotic Resistance
What is being tested?
Fecal Microbiota Transplantation (FMT)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
2 sitesCanada
Study dates
4 Nov 2019to Nov 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Renal transplant patient inclusion criteria:

  • 18 years or older
  • Able to provide informed consent
  • Positive for one of the target MDRO by rectal or stool culture tests

FMT stool donor inclusion criteria:

  • Able to provide informed consent
  • Able to complete donor screening
  • Able to adhere to FMT stool collection and testing procedures

Renal transplant patient exclusion criteria:

  • Still in hospital at week 7 following organ transplantation
  • Pregnant or planning to become pregnant
  • Breastfeeding
  • Participating in another interventional or investigational study
  • Neutropenic (ANC < 0.5)
  • Presence of colostomy or ileostomy
  • Has an active intestinal infection
  • Fever > 38.0 or white blood count (WBC) count > 15,000
  • Are taking a non-dietary probiotic supplement
  • Require or are expected to require systemic antimicrobial therapy other than Pneumocystis prophylaxis or cytomegalovirus (CMV) therapy during the study period
  • Has a severe underlying disease with anticipated survival less than 6 months
  • Are unable to tolerate FMT or enema for any reason, or where their physician believes for any reason that FMT might pose a health risk to the subject
  • Subjects who report a history of anaphylactoid food allergy will not be excluded but these allergies will be noted and donors will be required to avoid ingestion of these foods for at least three days prior to donation

FMT stool donor exclusion criteria:

  • Presence of any of the following by stool examination: vancomycin-resistant Enterococci (VRE), Salmonella, Shigella, shiga toxin-producing E. coli, Yersinia, Campylobacter, extended spectrum beta-lactamase (ESBL) producing organisms or carbapenemase-producing Enterobacteriaceae (CRE), pathogenic ova or parasites, C. difficile toxin B (by PCR), or rotavirus, adenovirus and norovirus
  • History of any type of active cancer aside from melanoma
  • Risk factors for acquisition of HIV, syphilis, Hepatitis B, Hepatitis C, prion or any neurological disease as determined by the donor questionnaire
  • History of gastrointestinal comorbidities, e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation or diarrhea, or colostomy or ileostomy
  • Receipt of blood transfusion from a country other than Canada in the preceding 6 months
  • Antibiotic use or any systemic immunosuppressive agents in the 3 months prior to stool donation
  • Receipt of any live vaccine within 3 months prior to stool donation
  • Any current or previous medical or psychosocial condition or behaviors which in the opinion of the investigator may pose risk to the recipients or the donor

Trial locations and contacts

2 sites in 1 country.

Amee Manges, MPH, PhD contact

604 707 2743

amee.manges@ubc.ca

Canada2 sites, 1 recruiting
  • Providence Health Care - St. Paul's Hospital

    Vancouver, British Columbia

    Active, not recruiting
  • Vancouver Coastal Health - Vancouver General Hospital

    Vancouver, British Columbia

    Theodore Steiner, MD

    Recruiting

Other trials in Canada

About this study

Official title: Fecal Microbiota Transplantation (FMT) for Intestinal Decolonization of Multidrug-resistant Opportunistic Pathogens

This is a trial designed to determine whether fecal microbiota transplantation (FMT) can eliminate highly drug-resistant bacteria from the intestinal tract of renal transplant patients. The primary goal of this study is to test whether oral gut decontamination followed by FMT using enema delivery will result in decolonization of the intestinal tract of renal transplant patients shortly after solid organ transplantation, thereby preventing difficult to treat post-transplant infections.

Read the detailed description

Contact the study principal investigator for the study protocol.

Being tested
Fecal Microbiota Transplantation (FMT)
Keywords
Fecal Microbiota Transplantation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fecal Microbiota Transplantation (FMT)Biological

    FMT using retention enema

Study groups in NCT04181112
Study groupRoleWhat they receive
Fecal microbiota transplantationExperimentalNot described
Receives: Biological: Fecal Microbiota Transplantation (FMT)
Fecal microbiota transplantation with antibiotic pre-treatmentExperimentalNot described
Receives: Biological: Fecal Microbiota Transplantation (FMT)
No intervention follow-upNo interventionNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The elimination of the target multi-drug resistant organism (MDRO), using culture and molecular test-based screening of recipient stool, at both the 14 and 30 days post-FMT.

    Measured: 3 years

Secondary outcomes (3)
  1. Compare proportions, type and timing of adverse events post-FMT

    Measured: 3 years

  2. Proportions of recolonization over 180 days

    Measured: 3 years

  3. Timing of recolonization over 180 days

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Nov 2019
  2. Study start4 Nov 2019
  3. Primary completionNov 2022 (estimated)
  4. Study completionNov 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04181112
Sponsor's protocol ID
H19-00782 FMT.MDRO.RCT.1
Status last verified
Oct 2021
First submitted
26 Nov 2019
Last updated
6 Oct 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Fecal Microbiota Transplantation (FMT) in people with Multi-antibiotic Resistance, run by University of British Columbia at 2 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Amee Manges, MPH, PhD (604 707 2743, amee.manges@ubc.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The elimination of the target multi-drug resistant organism (MDRO), using culture and molecular test-based screening of recipient stool, at both the 14 and 30 days post-FMT. (time frame: 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in